Table 2.
Functional characterization of anti-factor H antibodies at onset and during remission during first year of follow-up.
| Onset (N = 44) | Remission | |||
|---|---|---|---|---|
| 3-months (N = 42) | 6-months (N = 37) | 12-months (N = 23) | ||
| Anti- FH antibody, AU/ml | 5,000 (2,123–163,829) | 409 (254–861) | 277 (154–893.6) | 408 (262–691.8) |
| Circulating FH immune complexes, AU/ml | 20,000 (7,168–44,480) | 806 (289–1,328) | 710 (244–1,681) | 1,004.5 (397–1,663) |
| Sheep red blood cell hemolysis, % | 72.8 (57.2–88.7) | 16.9 (13.5–22.6) | 14.6 (13–19.1) | 13 (5.4–20) |
| Free FH, mg/l | 64 (34–106) | – | 553 (376–630) | 779 (571–1,071) |
| Soluble terminal complement complex (sC5b-9), ng/ml | 1,510 (832–2,220) | – | 351 (260–720) | 355.5 (232.5–642.5) |
| Complement C3, mg/dl | 60.7 (48.7–82.6) | – | 108.9 (95.5–129.9) | 121.9 (94.4–130.2) |
P < 0.001 for all comparisons from onset.
Values are median (interquartile range); AU, arbitrary units; FH, factor H.
Normal ranges: Anti-FH antibody <150 AU/ml; circulating FH-immune complexes <110 AU/ml; sheep red blood cell hemolysis 16.9 ± 2.1%; median free FH 720 (459–810) mg/l; median sC5b-9 195.3 (151.1–292.5) ng/ml; C3 90–130 mg/dl.